The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid ...

THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, ...

Lexicon Pharmaceuticals, Inc. is downgraded to Hold due to repeated FDA rejections of ZYNQUISTA for T1D and catalysts. Read more on LXRX stock here.

Our End-of-Phase 2 meeting with FDA was productive and provided Lexicon with the insights needed to design a robust Phase 3 program, with the goal of making the first non-opioid DPNP medicine ...

Lexicon Pharmaceuticals is actively working to create shareholder value by pursuing new indications for the lead drug sotagliflozin. The company reported $0.7 million in Inpefa sales for Q4 2023, ...

Lexicon Pharmaceuticals has appointed Scott Coiante as its new senior vice president and chief financial officer, effective January 2, 2025. Coiante brings over 35 years of experience in finance ...

Lexicon Pharmaceuticals, Inc. announced that it will release its financial results for the fourth quarter and full year 2024 on March 6, 2025, after market close. Following the release, the company's ...

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) stock is trading higher on Friday. Penny stock Lexicon Pharmaceuticals entered into an exclusive license agreement with Novo Nordisk A/S (NYSE:NVO) on Friday ...